Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT03287232 Completed - Clinical trials for Hypoactive Sexual Desire Disorder

Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

Start date: October 16, 2017
Phase: Phase 3
Study type: Interventional

The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.

NCT ID: NCT03286881 Completed - Depression Clinical Trials

Brief Evidence-based Psychological Treatments for Emotional Disorders

PsycBrief
Start date: January 15, 2017
Phase: N/A
Study type: Interventional

The present work aims to develop a randomized clinical trial with a sample of 165 patients diagnosed with an emotional disorder. All participants are tested by several self-reports related to common mental disorders in a repeated measures design, pre and post treatment as well as a six month follow up. We think this study will demonstrate that brief psychological treatments should be prioritized over pharmacological treatment for such pathologies in the Primary or Secondary Care context to improve the patient´s quality of life while simultaneously reducing costs.

NCT ID: NCT03284671 Completed - Clinical trials for Obsessive-compulsive Disorders and Symptoms

tDCS Stimulation to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder-Pilot Study

tDCS-TOC
Start date: February 19, 2016
Phase: N/A
Study type: Interventional

The purpose is to show that bifocal tDCS with an anodal stimulation on the orbitofrontal cortex and cathodic stimulation on supplementary motor areas is an effective treatment for patients with resistant and severe obsessive compulsive disorders.

NCT ID: NCT03283839 Recruiting - Clinical trials for Temporomandibular Disorder

Consequences of Temporomandibular Disorder on Balance Control

DAM
Start date: June 19, 2017
Phase: N/A
Study type: Interventional

To evaluate the effects of the temporomandibular disorder (TMD) and its therapeutic care on postural control in somato-sensory and visual sensitization compared to control subjects matched on age, sex and lifestyle. Parameters will be estimated by measures realized before the therapeutic care of the TMD (T0), then 2, 3 and 5 months after the starting care, both in TMD patients and control subjects. To evaluate also the effects of the TMD and its therapeutic care on balance control in various contexts of multi-sensory stimulation, orientation function, pain and tinnitus.

NCT ID: NCT03283670 Completed - Clinical trials for Depressive Disorder, Major

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NARSAD
Start date: November 22, 2016
Phase: Phase 2
Study type: Interventional

The purpose of the study aims to determine whether different concentrations of nitrous oxide (N2O) have different antidepressant effects for adults with treatment-resistant major depression.

NCT ID: NCT03280966 Not yet recruiting - Clinical trials for Pathological Gambling

Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder

NalGamb
Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

Primary objective: *To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder The secondary objectives of the study are: - To determine the effects of naloxone hydrochloride nasal spray on gambling severity, frequency and time, internet use, self-efficacy, quality of life, alcohol consumption, depression - To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of gambling disorder

NCT ID: NCT03280368 Completed - Atrial Fibrillation Clinical Trials

Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation

ARCADE
Start date: June 2014
Phase:
Study type: Observational

In patients with non-valvular atrial fibrillation treated with dabigatran etexilate, the level of adherence will be measured using a questionnaire, the Danish National Prescription Registry and pillcount and will be related to plasma levels of dabigatran measured by liquid chromatography tandem mass spectrometry (LC-MS/MS) and coagulation assays. The aim of the study is to measure the level of adherence and evaluate the usefulness of different coagulation assays to measure adherence in these patients. Furthermore, the aim is to determine the correlation between the anticoagulant effect of dabigatran using different coagulation assays and plasma levels of dabigatran. Most studies so far have been performed in vitro with plasma samples spiked with dabigatran. In this study the present knowledge from results of coagulation assays in dabigatran spiked plasma samples will be compared to the results of coagulation assays using blood samples from real-life patients.

NCT ID: NCT03278171 Completed - Clinical trials for Post Traumatic Stress Disorder

Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit

STRESSREA
Start date: September 20, 2017
Phase:
Study type: Observational

Post-traumatic stress disorder (PTSD) is a psychiatric pathology noticed in the DSM-5, in troubles due to a traumatism or a stress factor and appearing at least 1 month after confrontation with trauma. This trouble can become chronic, and be the source of psychiatric and somatic comorbidities, which themselves have personal, professional and economic consequences at the level of the individual and society. Some studies looked at the psychological effects induced by a stay in intensive care unit (ICU) since few years. The emergence of PTSD in these patients has been described, with an incidence varying from 4% to 60%. The literature is contradictory about identified risk factors for PTSD. It's not possible to design a screening of these patients actually, only focused on the risk factors. It has been shown that the presence of acute stress trouble (presence of symptoms during the first month after the traumatism) was a risk factor for PTSD. Early detection of acute stress disorder could be a way to screen risk of emergence of a post-intensive care PTSD. Post-intensive care consultations have been done at 6 months, but not systematically. Only few symptoms are looked for and a sizable part of this population were not being followed probably due to a non-diagnosed-PTSD. In case of the emergence of a post-intensive care PTSD, those patients will never be diagnosed and treated, favoring all complications linked to this trouble. Associated with other factors, IES-R (Impact Event Scale Revisited) at the ICU exit would permit an exhaustive screening of patients at risk for PTSD and could permit to propose them an adapted care and then limit the emergence of PTSD and its consequences.. In this study, the investigators will screen acute stress symptoms within 8 days following the ICU's exit, using the IES-R, in order to evaluate his ability to predict the emergence of a PTSD at three months. IES-R is an auto-questionnaire, easy and fast with good psychometrics capacities for PTSD.

NCT ID: NCT03277339 Completed - Clinical trials for Generalized Anxious Disorders

Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders

Insula-TOP
Start date: January 19, 2017
Phase: Phase 4
Study type: Interventional

Multicenter study comparing paroxetine (n=30) versus thermal cure (n=30) in patients with a diagnosis of Generalised Anxiety Disorders

NCT ID: NCT03277222 Terminated - Clinical trials for HIV Associated Neurocognitive Disorder (HAND)

Intranasal Treatment of HIV-associated Neurocognitive Disorders

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

This study aims to see whether intranasal insulin is an effective treatment for problems with memory, concentration, slowed thinking, or any other cognitive function in people living with HIV/AIDS. This group of signs and symptoms are called 'HIV-associated neurocognitive disorders' or HAND. HAND can affect people living with HIV/AIDS even when they receive potent anti-HIV treatments. Treatment of HAND by specific medication or other means is not yet available. Intranasal insulin treatment has virtually no side-effects, and has already been tested in people with Alzheimer's disease, where it showed beneficial effects on memory, mood and quality of life